Literature DB >> 10626184

Expression of the midkine gene in human hepatocellular carcinomas.

N Koide1, H Hada, T Shinji, K Ujike, S Hirasaki, Y Yumoto, T Hanafusa, K Kadomatsu, H Muramatsu, T Muramatsu, T Tsuji.   

Abstract

BACKGROUND/AIMS: Aberrant expression of Midkine (MK) has been found in various human carcinomas including hepatocellular carcinoma (HCC). The aim of study is to identify the incidence of MK expression in tumor and surrounding non-tumor tissues of the liver, and to find the correlation of MK expression with other tumor markers.
METHODOLOGY: Liver tissues were obtained from 16 patients with HCC and 4 with metastatic liver cancer. Background diseases of the HCC patients include liver cirrhosis and chronic hepatitis of type B or C. RNA was prepared from both cancerous and surrounding non-cancerous tissues, and analyzed for the presence of MK mRNA by RT-PCR, PCR-Southern blot, and Northern blot analysis.
RESULTS: MK expression was detected in 12 (75%) of 16 HCCs by PCR-Southern blot analysis, the most sensitive of the 3 methods. Three of 9 surrounding cirrhotic tissues were weakly positive for MK expression, and none of chronic hepatitis and 4 normal tissues were negative. No significant difference was found in clinical and pathological parameters between MK negative and positive cases. Among metastatic cancers, 1 of gastric origin was positive for MK expression, but 1 each of chorangiocellular, gall bladder, and gastrinoma origin was negative.
CONCLUSIONS: These results suggest that MK is expressed in the majority of HCC tissues and rarely in surrounding tissues in chronic liver diseases.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10626184

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  11 in total

1.  Construction of a fusion protein expression vector MK-EGFP and its subcellular localization in different carcinoma cell lines.

Authors:  Li-Cheng Dai; Di-Yong Xu; Xing Yao; Li-Shan Min; Ning Zhao; Bo-Ying Xu; Zheng-Ping Xu; Yong-Liang Lu
Journal:  World J Gastroenterol       Date:  2006-12-21       Impact factor: 5.742

Review 2.  Biomarker development for hepatocellular carcinoma early detection: current and future perspectives.

Authors:  Shreya Sengupta; Neehar D Parikh
Journal:  Hepat Oncol       Date:  2017-11-17

Review 3.  Measuring midkine: the utility of midkine as a biomarker in cancer and other diseases.

Authors:  D R Jones
Journal:  Br J Pharmacol       Date:  2014-06       Impact factor: 8.739

4.  The signal peptide of the tumor-shared antigen midkine hosts CD4+ T cell epitopes.

Authors:  Jerome Kerzerho; Aurélie Schneider; Emmanuel Favry; Florence Anne Castelli; Bernard Maillère
Journal:  J Biol Chem       Date:  2013-04-03       Impact factor: 5.157

5.  Wnt/β-catenin up-regulates Midkine expression in glioma cells.

Authors:  Shi-Lei Tang; Yuan-Lin Gao; Xiao-Bing Chen
Journal:  Int J Clin Exp Med       Date:  2015-08-15

6.  Tumour antigen expression in hepatocellular carcinoma in a low-endemic western area.

Authors:  K Sideras; S J Bots; K Biermann; D Sprengers; W G Polak; J N M IJzermans; R A de Man; Q Pan; S Sleijfer; M J Bruno; J Kwekkeboom
Journal:  Br J Cancer       Date:  2015-06-09       Impact factor: 7.640

7.  Suppression of midkine gene promotes the antitumoral effect of cisplatin on human gastric cancer cell line AGS in vitro and in vivo via the modulation of Notch signaling pathway.

Authors:  Wenyan Tian; Jiaqing Shen; Weichang Chen
Journal:  Oncol Rep       Date:  2017-06-22       Impact factor: 3.906

8.  Biomarkers for the Early Detection of Hepatocellular Carcinoma.

Authors:  Neehar D Parikh; Anand S Mehta; Amit G Singal; Timothy Block; Jorge A Marrero; Anna S Lok
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-04-01       Impact factor: 4.254

9.  A promoter region of the midkine gene that is frequently expressed in human hepatocellular carcinoma can activate a suicide gene as effectively as the alpha-fetoprotein promoter.

Authors:  M Tomizawa; L Yu; A Wada; T Tamaoki; K Kadomatsu; T Muramatsu; S Matsubara; K Watanabe; M Ebara; H Saisho; S Sakiyama; M Tagawa
Journal:  Br J Cancer       Date:  2003-09-15       Impact factor: 7.640

10.  Midkine promoter-based conditionally replicative adenovirus therapy for midkine-expressing human pancreatic cancer.

Authors:  Eiji Toyoda; Ryuichiro Doi; Kazuhiro Kami; Tomohiko Mori; Daisuke Ito; Masayuki Koizumi; Atsushi Kida; Kazuyuki Nagai; Tatsuo Ito; Toshihiko Masui; Michihiko Wada; Masatoshi Tagawa; Shinji Uemoto
Journal:  J Exp Clin Cancer Res       Date:  2008-08-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.